Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Financing

NervGen Pharma reports C$80.1M cash at Q3 2026 after May public offering; nine-month net income of C$2.5M

NervGen Pharma, a spinal cord injury-focused biotech listed on Nasdaq, filed unaudited interim financials for the period ended September 30, 2026. Cash rose to C$80.1M from C$22.1M at year-end, mainly from a May 2026 public offering and option and warrant exercises. A C$33.9M unrealized gain on the warrant derivative produced nine-month net income of C$2.5M, even though operating expenses rose to C$30.3M and the company posted a Q3 net loss of C$6.4M.

16 Nov 2026 · Nervgen Pharma Corp. NGEN · Company news

Company's press release (SEC filing): Nervgen Pharma Corp. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →